724
HETEROCYCLES, Vol. 86, No. 1, 2012
to afford benzamide (27 mg, 72%) and 1211 (12 mg, 19%). mp 152-155 °C. 1H NMR : 2.44 (s, 3H, CH3),
3.69 (m, 2H, CH2CH2OH), 4.31 (t, 2H, J = 6.1 Hz, CH2CH2OH), 4.88 (t, 1H, J = 5.9 Hz, OH), 7.33 (m,
1H, H6), 7.55 (m, 1H, H7), 7.65 (m, 1H, H8), 7.74 (m, 1H, H5). MS (EI, m/z, %): 204 (M+, 41). Anal.
Calcd for C11H12N2O2: C, 64.69; H, 5.92; N, 13.72. Found: C, 64.91; H, 6.19; N, 13.42.
Formation of 3-(chloromethyl)-1-methylquinoxalin-2(1H)-one (13) and 3-(acetyloxymethyl)-
1-methylquinoxalin-2(1H)-one (14). A mixture of 2 (293 mg, 1 mmol), CH2Cl2 (17 mL) and AcCl (0.14
mL, 2 mmol) was heated under reflux for 4 h. The volatile components were evaporated under reduced
pressure and the solid residue was purified by radial chromatography (petroleum ether/AcOEt, 5:1) to
give 1311 (143 mg, 67%), followed by radial chromatography (petroleum ether/AcOEt, 1:1) to give 14 (17
1
mg, 7%) and benzamide (103 mg, 85%). Compound 13: mp 165169 °C (MeOH). H NMR : 3.66 (s,
3H, CH3), 4.79 (s, 2H, CH2), 7.43 (m, 1H, H6), 7.61 (m, 1H, H8), 7.70 (m, 1H, H7), 7.85 (m, 1H, H5).
MS (EI, m/z, %): 208 (M+, 100). Anal. Calcd for C10H9ClN2O: C, 57.57; H, 4.35; N, 13.43. Found: C,
57.46; H, 4.30; N, 13.27. Compound 14: mp 4950 °C. 1H NMR : 2.16 (s, 3H, CH3), 3.64 (s, 3H, CH3),
5.23 (s, 3H, CH2), 7.41 (ddd, 1H, J = 1.5, 6.8, 8.3 Hz, H6), 7.60 (dd, 1H, J = 1.5, 8.3 Hz, H8), 7.67 (ddd,
1H, J = 1.5, 6.8, 8.3 Hz, H7), 7.81 (dd, 1H, J = 1.5, 8.3 Hz, H5). MS (EI, m/z, %): 232 (M+, 29). Anal.
Calcd for C12H12N2O3: C, 62.06; H, 5.21; N, 12.06. Found: C, 62.29; H, 5.62; N, 11.62.
ACKNOWLEDGEMENTS
We thank the Slovenian Research Agency for financial support (P1-0230-0103).
REFERENCES
1. For reviews, see: (a) A. E. A. Porter, Pyrazines and their Benzo Derivatives in Comprehensive
Heterocyclic Chemistry, Vol. 3, ed. by A. R. Katritzky and C. W. Rees, Pergamon Press, 1984, p.
173; (b) N. Sato, Pyrazines and their Benzo Derivatives in Comprehensive Heterocyclic Chemistry II,
ed. by A. R. Katritzky, C. W. Rees, and E. F. V. Scriven, Vol. 6, ed. by A. J. Boulton, Pergamon
Press, 1996, p. 244; (c) A. Husain and D. Madhesia, Journal of Pharmacy Research, 2011, 4 , 924.
2. For examples, see: (a) S. Kamila and E.R. Biehl, Heterocycles, 2006, 68, 1931; (b) F.-W. Wu, R.-S.
Hou, H.-M. Wang, I.-J. Kang, and L.-C. Chen, Heterocycles, 2011, 83, 2313; (c) M. A. Ibrahim,
Heterocycles, 2011, 83, 2689.
3. For examples, see: (a) I. Mušič, A. Golobič, and B. Verček, Synlett, 1998, 983; (b) K. Čuček and B.
Verček, Synlett, 1999, 120; (c) T. Trček, A. Meden, and B. Verček, Synlett, 2000, 1458; (d) T. Jug,
M. Polak, T. Trček, and B. Verček, Heterocycles, 2002, 56, 353; (e) T. Trček and B. Verček,
Synthesis, 2006, 3437; (f) K. Čuček, A. Golobič, and B. Verček, Heterocycles, 2007, 73, 555; (g) K.
Čuček and B. Verček, Synthesis, 2008, 1741; (h) I. Mušič and B. Verček, Heterocycles, 2011, 83,